This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Original Research

Obsessive-Compulsive Symptoms in Patients With Schizophrenia: A Naturalistic Cross-Sectional Study Comparing Treatment With Clozapine, Olanzapine, Risperidone, and No Antipsychotics in 543 Patients

Albertine A. Scheltema Beduin, MD; Marije Swets, MD; Marise Machielsen, MD; Nikie Korver, MsC; and the Genetic Risk and Outcome of Psychosis Investigators

Published: November 15, 2012

Article Abstract

Objective: To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking clozapine, olanzapine, or risperidone or taking no antipsychotic medication.

Method: Baseline data of the Genetic Risk and Outcome of Psychosis study were collected between April 2005 and October 2008. We conducted a naturalistic cross-sectional study of 543 patients with schizophrenia and related disorders, who were recruited from multiple mental health centers, including inpatient and outpatient clinics, across The Netherlands. The patients met Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria and were taking no antipsychotic medication or taking clozapine, olanzapine, or risperidone. OCS severity was measured with the Yale-Brown Obsessive Compulsive Scale. We compared patients to a sample of 575 healthy controls.

Results: Prevalence of OCS in patients was significantly higher than in the control sample, 23.4% versus 4.9% (χ2 = 73.8, P < .001). Patients taking clozapine reported OCS significantly more often during the last week (38.9%), when compared to patients taking olanzapine (20.1%, χ2 = 10.02, P = .002) or risperidone (23.2%, χ2 = 5.96, P = .015) and patients taking no antipsychotics (19.6%, χ2 = 8.20, P = .004). Patients taking clozapine for 6 months or longer reported OCS significantly more often than patients taking clozapine for less than 6 months, 47.3% versus 11.8% (χ2 = 6.89, P = .009).

Conclusions: Treatment with clozapine in patients with schizophrenia is associated with a higher prevalence of OCS, especially when patients have been taking clozapine for 6 months or longer. We cannot rule out the possibility that this association is related to illness characteristics. Patients treated with risperidone or olanzapine or without treatment with antipsychotic medication had comparable prevalence of OCS, all significantly higher than the control sample.

J Clin Psychiatry 2012;73(11):1395-1402



Submitted: May 23, 2012; accepted July 6, 2012 (doi:10.4088/JCP.11m07164).


Corresponding author: Lieuwe de Haan, MD, PhD, AMC, Academic Psychiatric Centre, Meibergdreef 5, 1105 AZ Amsterdam, The Netherlands, (

Volume: 73

Quick Links:

Continue Reading…

Subscribe to read the entire article


Buy this Article as a PDF